SCHEMBL5728707

SCHEMBL5728707

Cc1[nH]c(C=C2C(=O)Nc3ccc(NC(N)=O)cc32)c(C)c1CCC(=O)N1CCN(C)CC1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT2 P31751 3/20 0.75
FLT3 P36888 7/20 0.61
AURKB Q96GD4 5/20 0.61
KDR P35968 11/20 0.55
FGFR1 P11362 9/20 0.55
PDGFRB P09619 8/20 0.55
EGFR P00533 2/20 0.53
RET P07949 4/20 0.53
FLT1 P17948 3/20 0.53
CHEK1 O14757 2/20 0.53
LCK P06239 2/20 0.53
CSF1R P07333 2/20 0.53
KIT P10721 2/20 0.53
PHKG2 P15735 2/20 0.53
FGFR3 P22607 2/20 0.53
AXL P30530 2/20 0.53
ALK Q9UM73 2/20 0.53
ABL1 P00519 1/20 0.53
FYN P06241 1/20 0.53
ABL2 P42684 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5728703 1.00 AKT2 (0.75) AKT2FLT3AURKBKDRFGFR1
SCHEMBL5728046 0.86 AKT2 (0.74) AKT2FLT3KDRFGFR1PDGFRB
SCHEMBL5728036 0.86 AKT2 (0.74) AKT2FLT3KDRFGFR1PDGFRB
SCHEMBL5728442 0.86 AKT2 (1.00) AKT2FLT3AURKBKDRFGFR1
SCHEMBL5728446 0.86 AKT2 (1.00) AKT2FLT3AURKBKDRFGFR1
SCHEMBL147370 0.78 KDR (0.60) FLT3AURKBKDRFGFR1PDGFRB
SCHEMBL15328223 0.78 AURKB (0.65) AKT2FLT3AURKBKDRFGFR1
SCHEMBL15328221 0.78 AURKB (0.65) AKT2FLT3AURKBKDRFGFR1
SCHEMBL5517198 0.77 KDR (0.68) AKT2FLT3AURKBKDRFGFR1
SCHEMBL5513920 0.77 KDR (0.69) AKT2FLT3AURKBKDRFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1680401-A2 INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER Schering Aktiengesellschaft (DE) 2006-07-19 EP claimed
WO-2005040116-A2 INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER SCHERING AKTIENGESELLSCHAFT (DE) 2005-05-06 WO claimed
US-20050090541-A1 Indolinone derivatives and their use in treating disease-states such as cancer SCHERING AKTIENGESELLSCHAFT (DE) 2005-04-28 US claimed
US-7105563-B2 Indolinone derivatives and their use in treating disease-states such as cancer SCHERING AKTIENGESELLSCHAFT (DE) 2006-09-12 US disclosed
EP-1680401-A2 INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER Schering Aktiengesellschaft (DE) 2006-07-19 EP disclosed
WO-2005040116-A2 INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER SCHERING AKTIENGESELLSCHAFT (DE) 2005-05-06 WO disclosed
US-20050090541-A1 Indolinone derivatives and their use in treating disease-states such as cancer SCHERING AKTIENGESELLSCHAFT (DE) 2005-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090541-A1 Indolinone derivatives and their use in treating disease-states such as cancer PDK3, PDK2, PDK4 AKT2 1359/4885FLT3 1806/4885AURKB 137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.